Splash Beverage Group Inc
$ 0.43
-3.14%
07 Aug - close price
- Market Cap 2,721,600 USD
- Current Price $ 0.43
- High / Low $ 0.46 / 0.42
- Stock P/E N/A
- Book Value -1.94
- EPS -41.08
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -5.33 %
- ROE -11.30 %
- 52 Week High 13.40
- 52 Week Low 0.25
About
Splash Beverage Group, Inc. produces, distributes and markets various beverages in the United States. The company is headquartered in Fort Lauderdale, Florida.
Analyst Target Price
$40.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-19 | 2025-07-11 | 2025-05-19 | 2025-02-26 | 2024-11-15 | 2024-08-14 | 2024-05-15 | 2024-03-29 | 2023-11-14 | 2023-08-14 | 2023-06-06 | 2023-03-31 |
| Reported EPS | -4.51 | -4.48 | -1.97 | -0.08 | -11.9 | -17.6 | -16 | -0.14 | -20.8 | -20.8 | -0.1 | -19.2 |
| Estimated EPS | -0.07 | -0.08 | -0.08 | -0.065 | -12.8 | -14.4 | -12.8 | -0.1 | -18.4 | -17.6 | -0.12 | -22.4 |
| Surprise | -4.44 | -4.4 | -1.89 | -0.015 | 0.9 | -3.2 | -3.2 | -0.04 | -2.4 | -3.2 | 0.02 | 3.2 |
| Surprise Percentage | -6342.8571% | -5500% | -2362.5% | -23.0769% | 7.0313% | -22.2222% | -25% | -40% | -13.0435% | -18.1818% | 16.6667% | 14.2857% |
Next Quarterly Earnings
| Aug 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SBEV
2026-08-05 12:13:05
Splash Beverage Group has partnered with Lupvindol Biosciences to advance CannEpil® through the FDA veterinary pathway for companion-animal oncology and chronic pain management. Splash will retain ownership of all intellectual property and commercialization rights. The collaboration aims to leverage Lupvindol's cannabinoid pharmaceutical development expertise, led by Dr. Hunter Land, to pursue a significant opportunity in animal health.
2026-08-04 05:10:22
This article provides financial data on Splash Beverage Group, Inc. (SBEV) listed on the NYSE American exchange, focusing on its forward price to sales ratio. The content appears to be a financial data page from TradingView, displaying basic market information, and legal disclaimers.
2026-08-01 00:39:29
This article provides a revenue breakdown for Splash Beverage Group, Inc. (SBEV) based on its AMEX listing. It highlights that the United States was the primary contributor to the company's revenue, generating $73.07K USD last year, following $4.16M USD the previous year. The data is sourced from TradingView and FactSet.
2026-07-31 08:09:50
Splash Beverage Group Inc (SBEV) has a current financial score of 7.07, placing it 17th out of 24 in the Beverages industry, indicating stable financial status but low operating efficiency. The company's latest quarterly revenue decreased by 99.04% year-over-year to 4.22K, and its net profit saw a 31.17% year-over-year decline. The article notes that relevant data for several financial metrics such as cash and cash equivalents, operating profit, and free cash flow have not been disclosed by the company.
2026-07-31 05:11:08
Splash Beverage Group (SBEV) stock surged over 64% in after-hours trading following an SEC filing. The company expanded its exclusive global license for the cannabinoid drug CannEpil with Argent BioPharma to include veterinary applications, specifically for companion-animal oncology and chronic pain treatment. This strategic move aims to tap into the growing global veterinary pain management market, valued at $2.6 billion in 2024.
2026-07-29 12:42:15
Splash Beverage Group (SBEV) has expanded its global license for CannEpil®, a proprietary pharmaceutical-grade cannabinoid formulation, to include veterinary therapeutic applications. This creates a second regulated pharmaceutical development platform alongside its existing human program, focusing initially on companion-animal oncology and chronic pain management. The company plans to pursue U.S. regulatory approval through the FDA Center for Veterinary Medicine's INAD and Conditional Approval pathways.
